Centocor | GenomeWeb

Centocor

The trial, called Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis to Define Unresponse Populations, or BATTER-UP, will enroll around 1,000 patients being treated by one of several marketed anti-TNF RA drugs: Enbrel, Remicade, Humira, Simponi, or Cimzia.

Under the CRADA, Ortho Biotech, a unit of J&J's Centocor, will have an option to exclusively license new inventions developed jointly or independently by NCI scientists. The collaboration will focus on engineering patients' T-cells to treat melanoma and possibly other types of cancers.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.